Rituximab treatment of ANCA-associated vasculitis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1748597
Abstract: ABSTRACT Introduction Rituximab, an anti–B-cell biological therapy, has been investigated in several clinical trials on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). Areas covered In this paper, the clinical trials and open-label studies on rituximab efficacy… read more here.
Keywords: rituximab; treatment anca; rituximab treatment; anca ... See more keywords
Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-215647
Abstract: We have read with interest the results of the MYCYC trial showing that mycophenolate mofetil (MMF) is not inferior to intravenous cyclophosphamide (CYC) in achieving a primary remission in the treatment of ANCA-associated vasculitides (AAV).1… read more here.
Keywords: mofetil step; treatment anca; mycophenolate mofetil; anca associated ... See more keywords